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performed to indirectly compare different strategies. METHODS: A pooled analysis 
of all available completed Novo Nordisk randomized clinical trials conducted in 
patients inadequately controlled on basal insulin (five trials) was used to com-
pare indirectly (1) IDegLira (N= 199) with (2) addition of liraglutide to basal insu-
lin (N= 225); (3) basal/bolus (BB) insulin (insulin glargine [IGlar] + insulin aspart) 
(N= 56); or (4) up-titration of IGlar (N= 329). All trials had comparable inclusion/
exclusion criteria, baseline characteristics and titration targets (in strategy 2 the 
basal insulin could not be up-titrated beyond baseline dose). Patient-level data 
were analyzed using multivariable statistical models with baseline heterogeneity 
accounted for using explanatory variables. RESULTS: For strategies 1–4, at end-of-
study (26 or 52 weeks) change in A1C (%) was –1.7, –1.3*, –1.4* and –1.0* respectively; 
change in body weight (kg) was –2.9, –3.5, +4.0* and +1.2*; mean daily basal insulin 
dose (U) was 37.8, 36.6, 62.4* and 60.7*; confirmed hypoglycemia rate (events/100 
patient-years) was 122.8, 124.4, 1060.8* and 286.1* (*p< 0.05 vs. IDegLira). Responder 
rates (percent of patients) were: with A1C < 7.0%: 64.7, 47.1*, 52.8 and 31.9*; with 
A1C < 7.0% and no hypoglycemia: 45.6, 35.5, 5.0* and 15.6*; with A1C < 7.0% and 
no hypoglycemia or weight gain: 39.1, 33.2, 0 and 7.7*. IDegLira was significantly 
better than strategies 3 and 4 for A1C reduction, weight reduction, insulin dose 
and hypoglycemia rate. Responder rates were greater with IDegLira versus strategy 
4. Results with IDegLira were similar (most endpoints) or better than those for 
strategy 2. CONCLUSIONS: These results suggest that IDegLira is more effective, 
with lower hypoglycemia rates, than up-titrated basal insulin or BB in patients 
uncontrolled on basal insulin.
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OBJECTIVES: To assess the relative efficacy of CANA, an inhibitor of sodium glu-
cose co-transporter 2, versus GLP-1 agonists, in second and third line for the 
treatment of T2DM patients, using NMA. METHODS: A systematic review of ran-
domized, controlled trials and Bayesian NMA were conducted to compare HbA1c 
lowering of CANA versus the GLP-1 agonists liraglutide and exenatide. NMAs 
were conducted separately by background treatment (metformin or metformin 
plus sulfonylurea) and trial duration (26/52/104 weeks). Networks were based on 
treatment- and dose-specific nodes. Non-informative priors were used. Relative 
efficacy was evaluated based on absolute differences in HbA1c reductions and 
Bayesian probabilities. RESULTS: In dual therapy, trials were identified reporting 
HbA1c reduction versus baseline at Weeks 26 (n= 8), 52 (n= 6), and 104 (n= 2). At 
Weeks 26 and 52, CANA 300/100mg had greater (Week 26: Δ = –0.17%/–0.28%) to 
similar (Week 52: Δ = –0.03%/0.09%) reductions versus exenatide 5µg, and lower/
similar versus exenatide 10µg (Week 26: Δ = 0.22%/0.10%). Reductions were greater 
for liraglutide 1.8/1.2mg, with differences versus CANA ranging between 0.20% and 
0.61%. At 104 weeks, reductions were similar for CANA 100mg (Δ = 0.04%/0.02%) 
and greater for CANA 300mg (Δ = 0.13%/0.11%) compared to liraglutide 1.2/1.8mg. 
In triple therapy, 5 trials reporting HbA1c reduction at Week 26 were identified 
to compare CANA versus liraglutide 1.8mg and exenatide 10/5µg. Reductions for 
CANA 100mg were similar to exenatide 5µg (Δ = –0.02%) and lower versus exena-
tide 10µg and liraglutide 1.8mg (Δ = –0.24% and –0.33%, respectively). Reductions 
for CANA 300mg were greater versus exenatide 5µg, and similar versus exenatide 
10µg and liraglutide 1.8mg (Δ = –0.01% and 0.08%). CONCLUSIONS: NMA results 
for dual therapy suggest increasing relative efficacy of CANA over time versus 
GLP-1 agonists, with CANA 300mg reaching similar HbA1c reductions as GLP-1 
agonists at 104 weeks. NMA results for triple therapy suggest at least similar 
efficacy for CANA 300mg.
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OBJECTIVES: Canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, 
is an effective and well-tolerated therapy in patients with type 2 diabetes mellitus 
(T2DM) in clinical trials. The objective of this study was to evaluate the impact of 
CANA on glycemic control in a real-world population. METHODS: A retrospective 
cohort analysis of adult patients with T2DM was conducted using 2013 data from 
the Inovalon MORE2 Registry, which consists of commercial, managed Medicare 
and Medicaid medical, pharmacy and laboratory claims. Patients with T2DM ≥ 18 
years of age with ≥ 60 days of canagliflozin supply and HbA1c test results within 120 
days pre- and ≥ 60 days post their first observed canagliflozin prescription fill were 
included. Patients with other types of diabetes, enrollment gaps and missing data 
were excluded. The difference between HbA1c levels pre- and post-canagliflozin was 
measured by a paired-t test. A subgroup analysis of patients with HbA1c> 7% at base-
line was also conducted. RESULTS: Of the 268 patients eligible patients with a claim 
for canagliflozin in 2013, 70% of patients received a 100mg dose. Median follow-up 
time to HbA1c measurement was 106 days. Mean (SD) age was 56.8 yrs (8.7), and 57% 
were male. The majority of the patients (63%) were covered by commercial payers. 
Mean HbA1c pre-canagliflozin was 8.3% (95% CI: 8.2%, 8.5%) and post-canagliflozin 
was 7.6% (95% CI: 7.5%, 7.8%). Mean difference in HbA1c pre-post was 0.7% (p< 0.001). 
In the subset of patients with HbA1c> 7% at baseline (81%), the mean difference 
pre-post canagliflozin was 0.9% (95% CI: 0.8%, 1.1%), p< 0.001. CONCLUSIONS: In a 
real-world setting, patients with T2DM had improved glycemic control as measured 
by HbA1c after receiving canagliflozin. HbA1c lowering in patients with baseline 
HbA1c> 7% was similar to the HbA1c improvement for all adults. The HbA1c results 
were generally similar to those observed in clinical trials.
socioeconomics, comorbidities and service year, patients receiving anti-diabetic 
medication were not associated with higher risk of dementia compared to non-
users (Odds Ratio [OR], 1.23; 95% confidence interval [CI], 0.94-1.62). We also found 
that exposure to specific anti-diabetic drugs were not related to the risk of devel-
oping dementia:metformin only (OR, 1.06; 95% CI, 0.69-1.64), sulfonylurea only (OR, 
1.04; 95% CI, 0.78-1.40), insulins only (OR, 0.77; 95% CI, 0.40-1.48), thiazolidinedione 
only (OR,0.77; 95% CI, 0.41-1.45). CONCLUSIONS: Use of anti-diabetic drugs, such 
as insulins, metformin, sulfonylurea and thiazolidinedione, are not associated 
with an altered risk of dementia among elderly.
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OBJECTIVES: Clinical studies suggest that adult type 2 diabetes (T2D) patients 
treated with the once-daily GLP-1 receptor agonist (RA) liraglutide 1.2 and 1.8mg 
achieve significant improvements in glycemic control and body weight with low 
risk of hypoglycemia. The objective of this study is to identify factors that predict 
clinical and economic outcomes associated with liraglutide therapy in a real-world 
setting. METHODS: Using the MarketScan® Laboratory Database, A1C outcomes and 
diabetes-related costs were evaluated in T2D patients initiating liraglutide (index 
event) between January 2010 and June 2012. Patients (N= 417) were required to have 
≥ 1 post-index claim for liraglutide and valid A1C values at baseline and within 
±45 days of the end of 6 months follow-up. Patients previously treated with GLP-1 
RAs or insulin, or evidence of type 1 diabetes, pregnancy or gestational diabetes 
at any time during the study period were excluded. Achievement of glycemic con-
trol (A1C < 7%) and diabetes-related costs were evaluated. Multivariable regression 
was used to identify significant (p< 0.05) predictors of glycemic control and to esti-
mate diabetes-related costs. RESULTS: Factors associated with increased odds of 
achieving A1C< 7% were early initiation (0-1 background oral anti-diabetics (OADs) 
vs. ≥ 2), adherence to liraglutide (proportion of days covered (PDC) ≥ 80%), pres-
ence of diabetic retinopathy or a disorder of lipid metabolism. Early initiation (0-1 
background OADs vs. ≥ 2) and higher out-of-pocket share of pharmacy costs were 
associated with significantly lower total diabetes-related costs at follow-up. Factors 
associated with significantly higher post-index total diabetes-related costs were 
higher baseline A1C, pre-index use of sulfonylureas, and the presence of diabetic 
retinopathy. The indicated impact of gender on clinical and economic outcomes, in 
this specific sample, varied by age. CONCLUSIONS: Predictors of glycemic control 
and diabetes-related costs among T2D patients treated with liraglutide in clinical 
practice include early liraglutide initiation, adherence, certain comorbidities and 
gender (age dependent).
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OBJECTIVES: In clinical trials, GLP-1 receptor agonists (GLP-1RA) dosed daily or 
once weekly (QW) have been shown to reduce HbA1c in patients with poorly 
controlled type 2 diabetes (T2D). However, little data exists on the real-world 
effectiveness of GLP-1RA in patients who have not attained HbA1c < 7.0% while on 
oral therapy. We evaluated glycemic response with GLP-1RA to inform decisions 
about initiating a GLP-1RA based on glycemic control. METHODS: This histori-
cal cohort study included adult T2D patients naïve to insulin and GLP-1RA in a 
national electronic medical record database initiating exenatide QW or liraglutide 
once daily between 2/1/2012 and 3/31/2013 (index date) with baseline HbA1c ≥ 7%. 
Changes in HbA1c from baseline to 6 months and 12 months were identified, as 
was the proportion with follow-up HbA1c < 7.0%. Outcomes were also assessed 
in patients with baseline HbA1c ≥ 9%. Paired t-tests and chi-square tests were 
used to test for significance of HbA1c change and proportion with HbA1c < 7% 
at follow-up. RESULTS: There were 1,474 patients initiating either exenatide 
QW (N= 376) or liraglutide (N= 1,098). Mean (SD) age was 57(11) years; 49.9% were 
female. Mean baseline HbA1c was 8.6%(1.4) overall and 10.2%(1.1) for the subset 
of 476 patients with baseline HbA1c ≥ 9%. At 6 months, mean HbA1c reduction 
was -0.9%(1.5) overall and -1.8%(1.8) in patients with baseline HbA1c ≥ 9% (p< .001 
for both). HbA1c reduction was similar at 12 months at -0.7%(1.5) overall and 
-1.5%(1.9) in patients with baseline HbA1c ≥ 9.0% (p< .001 for both). At 12 months, 
the proportion attaining HbA1c < 7.0% was 25.8% overall and 13% in patients with 
baseline HbA1c ≥ 9%. CONCLUSIONS: GLP-1RA treatment was associated with a 
significant reduction in HbA1c for up to 12 months in a real-world setting in all 
patients; results were more pronounced when baseline HbA1c ≥ 9%. GLP-1RAs may 
be considered in insulin-naïve patients with poorly controlled T2D.
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OBJECTIVES: IDegLira is a once-daily combination of insulin degludec (IDeg) 
and liraglutide. Trials directly comparing IDegLira with alternative strategies for 
intensifying basal insulin are ongoing. While awaiting results, this analysis was 
